What Happened
All the chairs of Europe’s big pharmaceutical companies have signed a public letter asserting that a shift in strategy is needed to close the gap to international rivals, Pharmaceutical Technology reported on 23 September 2026. The publication frames the letter as a response to what the signatories describe as ringing alarm bells over the continent’s eroding position in the sector. The report does not set out specific policy demands, investment figures or a timetable. No company named in the report has announced a change to its manufacturing or distribution footprint as a result.
What a European Footprint Debate Means for UK Medicine Flows
Nothing changes for a UK importer this week, and that is worth stating plainly. A letter from company chairs is advocacy, not regulation, and no marketing authorisation, customs procedure or supply route is altered by it. The reason UK shippers should still read it is that the letter is about where medicines get made. The UK draws a large share of its finished medicines and active ingredients from plants in Ireland, Belgium, Germany, France and Italy, and those flows move mainly by road on FTL and groupage services, with air used for cold chain and time-critical lines.
Manufacturing footprint decisions are slow, and they reshape freight for a decade once taken. If European investment weakens relative to the United States and Asia, UK buyers gradually find more of their supply arriving on long haul lanes rather than on 2 to 4 day road transits from the near continent. That shift carries a different risk profile entirely: longer lead times, more inventory held to cover them, and customs entries filed against third country origins rather than EU preferential origin. Specialist freight forwarding services tend to see these changes in booking patterns well before they appear in trade statistics.
The near term action is to map your own exposure rather than react to the letter. List your top medicine and ingredient lines by manufacturing site, not by supplier name, because a single supplier often ships from several countries. For each, record the mode, the transit time and the origin declared on the CDS entry. Northern Ireland movements need separate treatment under the Windsor Framework medicines arrangements that took full effect on 1 January 2025, where MHRA authorisation applies UK wide and packs carry UK only labelling. Knowing which lines sit where takes a few hours and removes most of the guesswork later.
Advocacy now, freight consequences later
Company chairs calling for a European strategy shift is a statement of intent, not a confirmed change. Treat it as an early signal rather than a forecast. The practical response for UK importers is to know which country each critical line is actually manufactured in, and what the transit time and customs treatment would be if that site moved.
Market Impact
European pharmaceutical manufacturing supports a dense road freight network into the UK, including temperature-controlled trailers running at 2 to 8C and 15 to 25C on scheduled departures. That density is what keeps groupage viable for smaller consignments of medicines and medical devices. Any sustained move of production away from Europe thins those schedules first at the margin, which typically shows up as fewer weekly departures and longer consolidation waits before it shows up in headline rates.
The counterweight is that Europe retains substantial installed capacity, regulatory infrastructure and skilled manufacturing that cannot be relocated quickly. Analysts expect any rebalancing to play out over years rather than quarters, and nothing in the Pharmaceutical Technology report suggests otherwise. For UK importers and exporters, the sensible reading is that road transits from the near continent remain the backbone of medicine supply for now, while air capacity and certified handling become steadily more important at the specialist end.
Reported by the Plexus Freight team, from Pharmaceutical Technology.
